>유럽 탁산 시장, 유형별(파클리탁셀, 도세탁셀, 카바지탁셀), 약물 유형( 제네릭 , 브랜드), 제형(리포좀, 나노입자, 고분자 미셀, 기타), 연령대(성인, 노인 ), 응용 분야( 유방암 , 비소세포 폐암, 췌장암, 난소암, 전립선암, 기타), 최종 사용자(병원, 외래 수술 센터, 전문 클리닉, 기타) 유통 채널(소매 판매, 직접 입찰) - 업계 동향 및 2029년까지의 전망.
시장 분석 및 통찰력
유럽 탁산 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 7.1%의 CAGR로 성장하고 있다고 분석합니다. 탁산 약물 치료의 기술적 발전과 컴퓨터 지원 진단의 증가하는 응용 프로그램이 예측 기간 동안 탁산 시장 성장을 견인하는 또 다른 요인입니다.
그러나 약물과 관련된 높은 비용과 혈전, 백혈구 감소증, 알레르기, 설사, 체중 감소와 같은 부작용은 시장 성장을 제한할 것입니다. 주요 시장 참여자의 파트너십 및 인수와 같은 전략적 제휴 채택은 탁산 시장 성장의 기회로 작용합니다.
보고서 메트릭 |
세부 |
예측 기간 |
2022년부터 2029년까지 |
기준 연도 |
2021 |
역사적 연도 |
2020 |
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시됨 |
다루는 세그먼트 |
유형별(파클리탁셀, 도세탁셀 및 카바지탁셀), 약물 유형(브랜드 및 제네릭), 제형(탁산을 함유한 리포좀 및 폴리머 미셀, 탁산의 하이드로겔 제형, 나노입자 제형 및 기타), 연령대별(성인 및 노인), 적용 분야(난소암, 유방암, 전립선암, 비소세포 폐암 및 기타), 최종 사용자(병원, 외래 수술 센터, 전문 병원 및 기타), 유통 채널(직접 입찰, 소매 판매) |
적용 국가 |
독일, 프랑스, 영국, 이탈리아, 스페인, 러시아, 스페인, 터키, 벨기에, 네덜란드, 스위스, 폴란드, 오스트리아, 헝가리, 리투아니아, 노르웨이, 아일랜드 및 기타 유럽 국가 |
시장 참여자 포함 |
Viatris Inc., Sandoz International GmbH(Novartis 사업부), sanofi-aventis US LLC, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG(Fresenius SE & Co. KGaA의 자회사), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Phar maceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC 등이 있습니다. |
탁산 시장 정의
The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as mitosis inhibitors and are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers. Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Taxanes are anticancer drugs that interfere with microtubule function, causing changes in mitosis and cellular death. Paclitaxel (Taxol) was first isolated from a yew tree, a small evergreen coniferous tree with a slow growth rate. As paclitaxel was initially scarce, docetaxel (Taxotere), a semisynthetic analogue of paclitaxel derived from the needles of the European yew tree Taxus baccata, was created. Docetaxel differs from paclitaxel in two chemical locations, making it more water soluble. Cabazitaxel is also a semisynthetic analogue of natural taxoids and was developed for its lack of affinity for P-glycoprotein, a common mediator of docetaxel resistance.
Furthermore, increasing use of taxane drugs due to rising prevalence of chronic diseases, surging prevalence of cancer, and increasing investment for healthcare infrastructure. These factors increase in the demand for taxane market has encouraged the key market players to implement newer technologies and strategies through product launches, acquisition, strategies and agreements.
Taxane Market Dynamics
Drivers
- The rise in incidence of cancer
Cancer has a major impact on society in the United States and worldwide. Cancer statistics describe what happens in large groups of people and provide a picture in time of the burden of cancer on society. Taxol, an antimitotic agent, used to treat cancer, blocks cancer cell growth by stopping cell division, resulting in cell death.
According to National Cancer Institute (NCI), a funded clinical trial found that 30 percent of patients with advanced ovarian cancer responded positively to taxane treatment. In clinical practice, the taxane is now standard therapy in metastatic breast cancer. Today, taxol is on the World Health Organization's Model List of Essential Medicines, a cytotoxic drug that kills cancer cells. It treats breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and AIDS-related Kaposi sarcoma.
- The funding by the government and investment in research and development
Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to the implementation of taxane by specialty treatment programs have been observed. Certain attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries. The issues around sustainability, productivity, and patient impact of drug development have never been and will not simply be a product of industry.
The funding by the government would result in the patient's safety, cost-savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.
Restraint
- Side effects of drugs incurred with the taxane drugs
Taxanes belong to a class of diterpenes. Taxane drugs (paclitaxel and docetaxel) are used as chemotherapeutic agents. Due to ongoing clinical trials, research studies, type of cancer, type of treatment plan, and drug dosage, the present high cost is expected to show a descending trend in the future. Taxane drugs are most effective for treating breast and prostate cancer. However, certain side effects have been reported. The adverse complications or side effects reported would lead to a decline in sales of the taxane drugs, which would limit the sales of the drugs. In addition, it would affect the reliability of manufacturers involved in this market and hence be expected to restrain the market growth.
Opportunity
-
Strategic initiative by market players
The demand for taxane market has increased in the U.S. and Europe owing to the timely treatment of alcohol and opioid disorders. These favorable factors enhance the need for taxane, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity to help in future growth and drive market growth.
Challenge
- The lack of skilled professionals required for taxane drug treatment
The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.
Physician supply is a term used to describe the number of trained physicians working in a healthcare system or labor market. It is dependent on the number of graduates and the retention rates of the profession. The physician shortage is a growing concern in many countries around the world.
The World Health Organization (WHO) estimated a global shortage of 4.3 million physicians, nurses, and other health professionals. Despite the strong evidence for the effectiveness of drugs in reducing morbidity and mortality, increasing treatment retention, and improving well-being for individuals with taxane, numerous barriers prevent broader access to taxane drug-based treatment.
Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers, with only a small minority rating themselves as competently providing supportive care. There is an urgent need for the education of professionals for the treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. Therefore, it is apparent that the availability of professionals with adequate skills is challenging the market growth.
Post COVID-19 Impact on Taxane Market
COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the taxane market.
Recent Developments
- In November 2022, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUS (insulin glargine), allowing for substitution at the pharmacy counter. Viatris is committed to improving patient access to sustainable, quality and more affordable healthcare. This has helped the company to grow their product portfolio.
- In May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech’s Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This prescription oral medicine is immediately available to patients via specialty pharmacies, with a $0 co-pay program for eligible patients. Sandoz is putting patients first by expanding access to generic pirfenidone for those with this rare disease, who will benefit from a more affordable, yet equally effective treatment. This has helped the company to grow its market position and business.
Taxane Scope and Market Size
Taxane market is segmented based on type, drug type, formulation, age group, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.
By Type
- Paclitaxel
- Docetaxel
- Cabazitaxel
On the basis of type, the Europe taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.
By Application
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Non-small Cell Lung Cancer
- Other
On the basis of application, the Europe taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and others.
By Drug Type
- Generics
- Branded
On the basis of drug type, the Europe taxane market is segmented into branded and generics.
By Formulation
- Liposomes
- Nanoparticles
- Polymeric Micelles
- Others
On the basis of formulation, the Europe taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others.
By Age Group
- Adult
- Geriatric
On the basis of age group, the Europe taxane market is segmented into adults and geriatric.
By End User
- Hospitals
- Ambulatory surgical centers
- Specialty clinics
- Others
On the basis of end user, the Europe taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others.
By Distribution Channel
- Direct tender
- Retail Sales
On the basis of distribution channel, the Europe taxane market is segmented into direct tender, retail sales.
Europe Taxane Market Regional Analysis
The taxane market is analyzed and market size information is provided by type, drug type, formulation, age group, application, end user and distribution channel.
The countries covered in the taxane market report are Germany, France, U.K., Italy, Spain, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Poland, Austria, Hungary, Lithuania, Norway, Ireland and rest of Europe.
In 2022, Germany is dominating due to the presence of key market players along the largest consumer market with high GDP. Germany is expected to grow due to rise in technological advancement in drug treatments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
탁산 시장은 또한 모든 국가의 의료 산업 성장에 대한 자세한 시장 분석을 제공합니다. 게다가 의료 서비스와 치료, 규제 시나리오의 영향, 탁산 시장과 관련된 추세 매개변수에 대한 자세한 정보를 제공합니다.
경쟁 환경 및 탁산 시장 점유율 분석
Taxane 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 있습니다. 제공된 위의 데이터 포인트는 Taxane 약물과 관련된 회사의 초점에만 관련이 있습니다.
Taxane 시장에서 거래하는 주요 기업으로는 Viatris Inc., Sandoz International GmbH(Novartis 사업부), sanofi-aventis US LLC, Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG(Fresenius SE & Co. KGaA의 자회사), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Phar maceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC 등이 있습니다.
합병, 인수 및 주요 시장 참여자 간의 합의와 같은 전략적 제휴는 탁산 약물의 성장을 더욱 가속화할 것으로 예상됩니다.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략을 통해 Taxane 시장에서 회사의 입지를 강화하고 조직의 수익 성장에도 도움이 됩니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 EUROPE TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 EUROPE TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 EUROPE TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 EUROPE TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 EUROPE TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 EUROPE TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 EUROPE TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 EUROPE TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 EUROPE TAXANE MARKET, BY REGION
16.1 EUROPE
16.1.1 GERMANY
16.1.2 FRANCE
16.1.3 U.K.
16.1.4 ITALY
16.1.5 RUSSIA
16.1.6 SPAIN
16.1.7 TURKEY
16.1.8 NETHERLANDS
16.1.9 SWITZERLAND
16.1.10 POLAND
16.1.11 BELGIUM
16.1.12 HUNGARY
16.1.13 AUSTRIA
16.1.14 NORWAY
16.1.15 IRELAND
16.1.16 LITHUANIA
16.1.17 REST OF EUROPE
17 EUROPE TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
TABLE 1 EUROPE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 EUROPE DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 EUROPE CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 EUROPE TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 EUROPE GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 EUROPE TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 EUROPE HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 EUROPE RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 EUROPE DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 EUROPE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 EUROPE TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 EUROPE TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 EUROPE PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 EUROPE DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 EUROPE CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 EUROPE TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 EUROPE ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 EUROPE GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 EUROPE TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 EUROPE TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 EUROPE RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 GERMANY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 GERMANY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 GERMANY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 GERMANY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 GERMANY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 GERMANY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 GERMANY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 GERMANY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 GERMANY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 GERMANY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 GERMANY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 GERMANY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 GERMANY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 FRANCE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 FRANCE TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 FRANCE TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 FRANCE TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 FRANCE PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 FRANCE DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 FRANCE CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 FRANCE TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 FRANCE ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 FRANCE GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 FRANCE TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 FRANCE TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 FRANCE RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 U.K. TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 U.K. PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 U.K. TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 U.K. TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.K. TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 U.K. PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 U.K. DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 U.K. CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 U.K. TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 U.K. ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 U.K. GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 U.K. TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.K. TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 U.K. RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 ITALY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 ITALY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 ITALY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 ITALY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 100 ITALY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 101 ITALY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 102 ITALY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 103 ITALY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 104 ITALY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 105 ITALY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 106 ITALY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 107 ITALY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 ITALY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 RUSSIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 RUSSIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 RUSSIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 112 RUSSIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 113 RUSSIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 114 RUSSIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 115 RUSSIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 116 RUSSIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 117 RUSSIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 118 RUSSIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 119 RUSSIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 120 RUSSIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 RUSSIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 RUSSIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 SPAIN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 SPAIN PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 SPAIN TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 126 SPAIN TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 127 SPAIN TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 128 SPAIN PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 129 SPAIN DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 130 SPAIN CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 131 SPAIN TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 132 SPAIN ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 133 SPAIN GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 134 SPAIN TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 SPAIN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 SPAIN RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 TURKEY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 TURKEY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 TURKEY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 140 TURKEY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 141 TURKEY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 142 TURKEY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 143 TURKEY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 144 TURKEY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 145 TURKEY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 146 TURKEY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 147 TURKEY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 148 TURKEY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 149 TURKEY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 150 TURKEY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 151 NETHERLANDS TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 NETHERLANDS PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 NETHERLANDS TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 NETHERLANDS TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 155 NETHERLANDS TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 156 NETHERLANDS PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 157 NETHERLANDS DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 158 NETHERLANDS CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 159 NETHERLANDS TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 160 NETHERLANDS ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 161 NETHERLANDS GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 162 NETHERLANDS TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 163 NETHERLANDS TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 164 NETHERLANDS RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 168 SWITZERLAND TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 169 SWITZERLAND TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 170 SWITZERLAND PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 171 SWITZERLAND DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 172 SWITZERLAND CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 173 SWITZERLAND TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 174 SWITZERLAND ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 175 SWITZERLAND GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 176 SWITZERLAND TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 SWITZERLAND TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 178 SWITZERLAND RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 179 POLAND TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 POLAND PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 POLAND TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 182 POLAND TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 183 POLAND TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 184 POLAND PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 185 POLAND DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 186 POLAND CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 187 POLAND TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 188 POLAND ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 189 POLAND GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 190 POLAND TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 191 POLAND TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 192 POLAND RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 193 BELGIUM TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 BELGIUM PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 BELGIUM TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 196 BELGIUM TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 197 BELGIUM TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 198 BELGIUM PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 199 BELGIUM DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 200 BELGIUM CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 201 BELGIUM TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 202 BELGIUM ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 203 BELGIUM GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 204 BELGIUM TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 BELGIUM TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 BELGIUM RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 207 HUNGARY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 HUNGARY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 HUNGARY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 210 HUNGARY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 211 HUNGARY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 212 HUNGARY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 213 HUNGARY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 214 HUNGARY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 215 HUNGARY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 216 HUNGARY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 217 HUNGARY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 218 HUNGARY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 219 HUNGARY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 220 HUNGARY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 221 AUSTRIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 AUSTRIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 AUSTRIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 224 AUSTRIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 225 AUSTRIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 226 AUSTRIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 227 AUSTRIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 228 AUSTRIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 229 AUSTRIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 230 AUSTRIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 231 AUSTRIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 232 AUSTRIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 233 AUSTRIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 234 AUSTRIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 235 NORWAY TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 NORWAY PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 NORWAY TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 238 NORWAY TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 239 NORWAY TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 240 NORWAY PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 241 NORWAY DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 242 NORWAY CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 243 NORWAY TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 244 NORWAY ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 245 NORWAY GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 246 NORWAY TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 247 NORWAY TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 248 NORWAY RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 249 IRELAND TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 IRELAND PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 251 IRELAND TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 252 IRELAND TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 253 IRELAND TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 254 IRELAND PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 255 IRELAND DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 256 IRELAND CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 257 IRELAND TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 258 IRELAND ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 259 IRELAND GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 260 IRELAND TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 261 IRELAND TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 262 IRELAND RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 263 LITHUANIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 264 LITHUANIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 265 LITHUANIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 266 LITHUANIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 267 LITHUANIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 268 LITHUANIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 269 LITHUANIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 270 LITHUANIA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 271 LITHUANIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 272 LITHUANIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 273 LITHUANIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 274 LITHUANIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 275 LITHUANIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 276 LITHUANIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 277 REST OF EUROPE TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 EUROPE TAXANE MARKET: SEGMENTATION
FIGURE 2 EUROPE TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE TAXANE MARKET: DROC ANALYSIS
FIGURE 4 EUROPE TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE EUROPE TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 EUROPE TAXANE MARKET: BY TYPE, 2021
FIGURE 17 EUROPE TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 EUROPE TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 EUROPE TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 EUROPE TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 EUROPE TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 EUROPE TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 EUROPE TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 EUROPE TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 EUROPE TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 EUROPE TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 EUROPE TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 EUROPE TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 EUROPE TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 EUROPE TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 EUROPE TAXANE MARKET: BY END USER, 2021
FIGURE 37 EUROPE TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 EUROPE TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 EUROPE TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 EUROPE TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 EUROPE TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 EUROPE TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 EUROPE TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 EUROPE TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 EUROPE TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 EUROPE TAXANE MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.